SI2680834T1 - A semi-aqueous aqueous pharmaceutical composition containing tapentadol - Google Patents
A semi-aqueous aqueous pharmaceutical composition containing tapentadol Download PDFInfo
- Publication number
- SI2680834T1 SI2680834T1 SI201231143T SI201231143T SI2680834T1 SI 2680834 T1 SI2680834 T1 SI 2680834T1 SI 201231143 T SI201231143 T SI 201231143T SI 201231143 T SI201231143 T SI 201231143T SI 2680834 T1 SI2680834 T1 SI 2680834T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pharmaceutical composition
- composition according
- tapentadol
- aqueous
- composition containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161449329P | 2011-03-04 | 2011-03-04 | |
| EP11003603 | 2011-05-03 | ||
| PCT/EP2012/000906 WO2012119729A1 (en) | 2011-03-04 | 2012-03-02 | Semisolid aqueous pharmaceutical composition containing tapentadol |
| EP12710026.1A EP2680834B1 (en) | 2011-03-04 | 2012-03-02 | Semisolid aqueous pharmaceutical composition containing tapentadol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2680834T1 true SI2680834T1 (en) | 2018-01-31 |
Family
ID=44652117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201231143T SI2680834T1 (en) | 2011-03-04 | 2012-03-02 | A semi-aqueous aqueous pharmaceutical composition containing tapentadol |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9446008B2 (enExample) |
| EP (3) | EP2680834B1 (enExample) |
| JP (3) | JP6027549B2 (enExample) |
| KR (2) | KR101911362B1 (enExample) |
| CN (1) | CN103501774A (enExample) |
| AU (2) | AU2012224954C1 (enExample) |
| BR (1) | BR112013022556A8 (enExample) |
| CA (1) | CA2828637C (enExample) |
| CY (1) | CY1119725T1 (enExample) |
| DK (1) | DK2680834T3 (enExample) |
| EA (2) | EA025194B1 (enExample) |
| ES (2) | ES2910085T3 (enExample) |
| HR (1) | HRP20171836T1 (enExample) |
| HU (1) | HUE037491T2 (enExample) |
| IL (2) | IL227826B (enExample) |
| LT (1) | LT2680834T (enExample) |
| MX (2) | MX344473B (enExample) |
| NO (1) | NO2680834T3 (enExample) |
| PL (1) | PL2680834T3 (enExample) |
| PT (2) | PT2680834T (enExample) |
| RS (1) | RS56692B1 (enExample) |
| SI (1) | SI2680834T1 (enExample) |
| WO (1) | WO2012119729A1 (enExample) |
| ZA (1) | ZA201306480B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX369121B (es) | 2011-03-04 | 2019-10-30 | Gruenenthal Gmbh | Formulacion farmaceutica acuosa de tapentadol para administracion oral. |
| US9446008B2 (en) * | 2011-03-04 | 2016-09-20 | Gruenenthal Gmbh | Semisolid aqueous pharmaceutical composition containing tapentadol |
| US8997860B2 (en) | 2011-08-05 | 2015-04-07 | Halliburton Energy Services, Inc. | Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices |
| US9395306B2 (en) | 2011-08-05 | 2016-07-19 | Halliburton Energy Services, Inc. | Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices |
| US8619256B1 (en) | 2012-09-14 | 2013-12-31 | Halliburton Energy Services, Inc. | Systems and methods for monitoring the properties of a fluid cement composition in a flow path |
| US20140076550A1 (en) | 2012-09-14 | 2014-03-20 | Halliburton Energy Services, Inc. | Systems and Methods for Detecting Microannulus Formation and Remediation |
| US9228940B2 (en) | 2012-09-14 | 2016-01-05 | Halliburton Energy Services, Inc. | Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof |
| US20160136112A1 (en) * | 2013-08-02 | 2016-05-19 | Ratiopharm Gmbh | Composition comprising tapentadol in a dissolved form |
| EP2845625A1 (en) | 2013-09-04 | 2015-03-11 | Grünenthal GmbH | Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome |
| TW201642843A (zh) * | 2015-03-27 | 2016-12-16 | 歌林達有限公司 | 他噴他多腸胃外給藥的穩定製劑 |
| EP3515412B1 (en) | 2016-09-23 | 2025-04-23 | Grünenthal GmbH | Stable formulation for parenteral administration of tapentadol |
| JP2021532112A (ja) * | 2018-07-24 | 2021-11-25 | ドクトア・アウグスト・ボルフ・ゲーエムベーハー・ウント・コンパニー・カー・ゲー−アルツナイミツテル | 抗コリン性化合物の局所用エマルション |
| EP3846852A4 (en) | 2018-09-07 | 2022-06-15 | R.P. Scherer Technologies, LLC | Solid or semisolid lipid based dosage form stabilization through curing and addition of low hlb surfactant(s) |
| CA3128882A1 (en) | 2019-03-18 | 2020-09-24 | Sunstar Americas, Inc. | Oral care composition |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775678A (en) * | 1984-10-01 | 1988-10-04 | Schering Corporation | Clotrimazole cream |
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| US6183758B1 (en) * | 1998-01-29 | 2001-02-06 | Highland Laboratories, Inc. | Phytochemicals, nutrients & medication absorption &/or treatment |
| US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
| DE10109763A1 (de) | 2001-02-28 | 2002-09-05 | Gruenenthal Gmbh | Pharmazeutische Salze |
| US20050176790A1 (en) * | 2001-02-28 | 2005-08-11 | Johannes Bartholomaus | Pharmaceutical salts |
| PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| CA2479350A1 (en) | 2002-03-15 | 2003-09-25 | Cypress Bioscience, Inc. | Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
| US20030191187A1 (en) | 2002-04-01 | 2003-10-09 | Lee Fang Yu | Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same |
| EP1545477A4 (en) | 2002-09-13 | 2006-11-22 | Cydex Inc | CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED WITH DERIVED CYCLODEXTRIN |
| US20040180915A1 (en) | 2003-03-14 | 2004-09-16 | Xanodyne Pharmacal, Inc. | Methadone-containing compositions for parenteral administration and method of use thereof |
| US20060111382A1 (en) | 2004-05-17 | 2006-05-25 | Pharmacofore, Inc. | Compositions and methods for treating or preventing pain |
| DK1612203T3 (da) | 2004-06-28 | 2007-12-03 | Gruenenthal Gmbh | Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid |
| AR053304A1 (es) | 2004-07-01 | 2007-05-02 | Gruenenthal Gmbh | Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion. |
| MX2007013583A (es) | 2005-04-28 | 2008-03-13 | Theraquest Biosciences Llc | Metodos y composiciones para tratar el dolor. |
| TWI329334B (en) | 2005-12-02 | 2010-08-21 | Chung Shan Inst Of Science | Manufacture method of electromagnetic interference layer for the plasma display panel |
| WO2007127158A2 (en) * | 2006-04-25 | 2007-11-08 | Croda, Inc | Modification of percutaneous absorption of topically active materials |
| HRP20110271T1 (hr) | 2006-04-28 | 2011-05-31 | Grnenthal Gmbh | Farmaceutska kombinacija koja sadrži 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i nsaid (nesteroidni antiinflamatorni lijek) |
| CN101431990B (zh) | 2006-04-28 | 2011-08-03 | 格吕伦塔尔有限公司 | 包含3-（3-二甲基氨基-1-乙基-2-甲基-丙基）-酚和对乙酰氨基酚的药物结合 |
| MX2009000911A (es) | 2006-07-24 | 2009-02-04 | Janssen Pharmaceutica Nv | Preparacion de (2r,3r)-3-(3-metoxifenil)-n,n,2-trimetilpentanamina . |
| DE102007012165A1 (de) | 2007-03-12 | 2008-09-18 | Grünenthal GmbH | Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes |
| EP1985292A1 (en) | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
| EP2219633A2 (en) * | 2007-11-23 | 2010-08-25 | Nectid, Inc. | Tapentadol compositions |
| CA2713128C (en) | 2008-01-25 | 2016-04-05 | Gruenenthal Gmbh | Pharmaceutical dosage form |
| ES2758831T3 (es) * | 2008-10-30 | 2020-05-06 | Gruenenthal Gmbh | Nuevas y potentes formas de dosificación de tapentadol |
| US20100227921A1 (en) | 2009-03-03 | 2010-09-09 | Shire Llc | Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof |
| US20100272815A1 (en) | 2009-04-28 | 2010-10-28 | Actavis Group Ptc Ehf | Amorphous form of tapentadol hydrochloride |
| US20110190267A1 (en) * | 2010-01-05 | 2011-08-04 | Shire Pharmaceuticals, Inc. | Prodrugs of opioids and uses thereof |
| JP5806287B2 (ja) * | 2010-03-30 | 2015-11-10 | フォスファジェニクス リミティド | 経皮送達パッチ |
| GB201006200D0 (en) * | 2010-04-14 | 2010-06-02 | Ayanda As | Composition |
| US20120270848A1 (en) * | 2010-10-22 | 2012-10-25 | Galleon Pharmaceuticals, Inc. | Novel Compositions and Therapeutic Methods Using Same |
| US9446008B2 (en) * | 2011-03-04 | 2016-09-20 | Gruenenthal Gmbh | Semisolid aqueous pharmaceutical composition containing tapentadol |
-
2012
- 2012-03-02 US US13/410,837 patent/US9446008B2/en active Active
- 2012-03-02 MX MX2013010100A patent/MX344473B/es active IP Right Grant
- 2012-03-02 LT LTEP12710026.1T patent/LT2680834T/lt unknown
- 2012-03-02 DK DK12710026.1T patent/DK2680834T3/en active
- 2012-03-02 RS RS20171334A patent/RS56692B1/sr unknown
- 2012-03-02 KR KR1020137026185A patent/KR101911362B1/ko not_active Expired - Fee Related
- 2012-03-02 KR KR1020187029861A patent/KR102039320B1/ko not_active Expired - Fee Related
- 2012-03-02 HU HUE12710026A patent/HUE037491T2/hu unknown
- 2012-03-02 HR HRP20171836TT patent/HRP20171836T1/hr unknown
- 2012-03-02 JP JP2013555798A patent/JP6027549B2/ja not_active Expired - Fee Related
- 2012-03-02 CN CN201280011678.9A patent/CN103501774A/zh active Pending
- 2012-03-02 NO NO12710026A patent/NO2680834T3/no unknown
- 2012-03-02 ES ES20188822T patent/ES2910085T3/es active Active
- 2012-03-02 PT PT127100261T patent/PT2680834T/pt unknown
- 2012-03-02 EP EP12710026.1A patent/EP2680834B1/en active Active
- 2012-03-02 EA EA201300988A patent/EA025194B1/ru not_active IP Right Cessation
- 2012-03-02 SI SI201231143T patent/SI2680834T1/en unknown
- 2012-03-02 PT PT201888229T patent/PT3766489T/pt unknown
- 2012-03-02 CA CA2828637A patent/CA2828637C/en not_active Expired - Fee Related
- 2012-03-02 ES ES12710026.1T patent/ES2654407T3/es active Active
- 2012-03-02 MX MX2016016703A patent/MX374468B/es unknown
- 2012-03-02 BR BR112013022556A patent/BR112013022556A8/pt not_active Application Discontinuation
- 2012-03-02 EP EP20188822.9A patent/EP3766489B1/en active Active
- 2012-03-02 PL PL12710026T patent/PL2680834T3/pl unknown
- 2012-03-02 EP EP17189139.3A patent/EP3290029B1/en not_active Not-in-force
- 2012-03-02 AU AU2012224954A patent/AU2012224954C1/en not_active Ceased
- 2012-03-02 EA EA201600442A patent/EA033171B1/ru not_active IP Right Cessation
- 2012-03-02 WO PCT/EP2012/000906 patent/WO2012119729A1/en not_active Ceased
-
2013
- 2013-08-06 IL IL227826A patent/IL227826B/en active IP Right Grant
- 2013-08-28 ZA ZA2013/06480A patent/ZA201306480B/en unknown
-
2016
- 2016-08-10 US US15/232,841 patent/US20160346229A1/en not_active Abandoned
- 2016-10-12 JP JP2016200663A patent/JP6259042B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-04 AU AU2017200040A patent/AU2017200040B2/en not_active Ceased
- 2017-11-29 JP JP2017228602A patent/JP6670283B2/ja not_active Expired - Fee Related
-
2018
- 2018-01-03 CY CY20181100006T patent/CY1119725T1/el unknown
- 2018-01-10 US US15/867,330 patent/US20180133174A1/en not_active Abandoned
- 2018-03-26 IL IL258357A patent/IL258357A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171836T1 (hr) | Polukruti vodeni farmaceutski pripravak koji sadrži tapentadol | |
| BR112014010275A2 (pt) | formulações para tratamento de diabetes | |
| BR112014029766A2 (pt) | composições contendo álcoois graxos, tensoativos catiônicos e n-acil-n-metilglucaminas | |
| HRP20210085T1 (hr) | Pripravci i postupci za liječenje disfunkcije meibomske žlijezde | |
| BR112017024934A2 (pt) | composições farmacêuticas tópicas | |
| RU2013141845A (ru) | Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа | |
| BR112014009097A2 (pt) | composição para uso na promoção de crescimento de osso saudável e/ou na prevenção e/ou tratamento das doenças dos ossos | |
| JPH07316075A (ja) | 皮膚外用剤 | |
| HRP20230726T1 (hr) | Topikalna formulacija za poticanje zarastanja rana | |
| JP2014517028A5 (enExample) | ||
| BRPI1009741A2 (pt) | composição, método para prevenir ou tratar a mucosite em paciente mamífero, composição farmacêutica para adminstração tópica, e uso de uma composição | |
| JP7664689B2 (ja) | 外用組成物 | |
| HRP20192246T1 (hr) | Marker za poremećaje kisele sfingomijelinaze i njegova uporaba | |
| HRP20191059T1 (hr) | Skup aktivnih sastojaka za topikalnu primjenu u restrukturiranju izmijenjene kožne barijere poslije kožnih bolesti | |
| BR112014026596A2 (pt) | composição pesticida sinérgica | |
| TWI716394B (zh) | 外用醫藥組合物 | |
| BR112015022084A2 (pt) | composições para uso em tratamento de distúrbios oculares com o uso de dipiridamol | |
| BR112015001627A2 (pt) | composição farmacêutica, respectivos usos e método para diminuir a frequência de micção | |
| Hwang et al. | Conditioned medium from LS 174T goblet cells treated with oxyresveratrol strengthens tight junctions in Caco-2 cells | |
| BRPI0417116A (pt) | usos de uma quantidade eficaz de ondansetron e composição para tratamento tópico de uma inflamação | |
| HRP20200504T1 (hr) | Lokalni preparati farmaceutskih i medicinskih proizvoda koji sadrže kombinacije sukralfata, hijaluronske kiseline, arginina i prirodnog hidratantnog sredstva | |
| BR112015027992A2 (pt) | uso de ácido petroselínico para combater desordens estéticas da figura do corpo | |
| SI2874614T1 (en) | Water-soluble film which has a healing effect | |
| WO2015100348A8 (en) | Keloid reduction using topical allantoin | |
| RU2015145451A (ru) | Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол |